General Test Services by BOC Sciences - PDF document

BOC Sciences ’ pharmaceutical separation and purification team are committed to the separation and identification of various impurities in the process of pharmaceutical research. Our experts are highly recognized by customers with their rich experience and problem - solving skills. Our Conventional Services for Impurity Isolation and Identification Impurity control is one of the core contents of drug quality control, and impurity research runs through the whole process of drug research and development. The i solation and identification of drug impurities are the most direct means for the study of impurities, and the separated impurities can be used for an in - depth study of qualitative, quantitative and safety. BOC Sciences provides comprehensive impurity identification .  Impurities - Quantitative To achieve quantitative analysis of impurities, we can separate impurities to obtain single components of impurities with good purity. We can add additional tests for impurities, including residual solvent (GC) and water content (Karl Fischer). BOC Sciences’ Unique Technology Liquid chromatography is widely used in downstream process crossing several industries. The technology be comes standard separation process to remove impurities or undesirable chemicals. Normally, the products are separated by affinity or hydrophobicity interaction with chosen functional columns. However, the state - of - art approach is limited in large biomolecu les separation because of the lack of control in pore size. In fact, although size exclusion separation provides higher resolution, the technique is seldom used in the processing step because of the high pressure needed. In addition to the conventional imp urity isolation and identification techniques, we provide an alternative method to remove small molecular impurities below six angstrom with 100 times larger throughput. The technology is developed based on patented materials possess well - defined six angst rom porosity to identify products from impurities. Moreover, the chromatography column is further designed to achieve 100 times better throughput. The patented materials are self - assembled, highly symmetrical, ultrasmall inorganic cages directed by su rfactant micelles, developed by research team at Cornell University. This new technology can be used for removal of precursor or small molecular impurities under 6 angstrom, such as carcinogens, degradation products and other unknown impurities. Our initia l proof - of - concept experiment has successfully demonstrated the viability of the technology for the separation of small molecule impurities that have recently led to recalls due to the unacceptable level of NDMA contaminations in the high - blood pressure dr ug, Ibesartan . Note: NDMA has attracted wide attention as being highly hepatotoxic and a known carcinogen in lab animals. High levels of exposure can cause reduced function of the kidneys and lungs. To date, NDMA has caused several recalls and warnings of successful drugs on the market, including Valsartan, Losartan, Irbesartan, Ranitidine and Metformin. The experiment results show that the genotoxic impurity, NDMA in drug products was removed more than 99% (from 2000 ppm to 1 ppm) by our new technology and the concentration went down below FDA’s daily allowance intake. At the same time, the yield of active pharmaceutical ingredient retained more than 90%. The measurements were conducted by following FDA published GC methods. Lower concentration can be ac hieved by repeating the separation process.